Medicinova
MNOV1.3413.95% ( +0.051 )
Medicinova (MNOV)
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medi...
- Open
- 1.290
- High
- 1.350
- Low
- 1.311
- Prev. Close
- 1.290
- Volume
- 52.02K
- Turnover
- 69.17K
- Avg Price
- 1.330
- Bid/Ask Ratio
- --
- Amplitude
- 3.02%
- 52wk High
- 1.960
- Volume Ratio
- 3.22
- Turnover Ratio
- 0.12%
Medicinova Analyst Rating
View MoreForecast & Rating
Jul 22, 2026Price forecast
$9.00571.14%
Forecast & RatingStrong buy
3analysts
- Strong buy66.67%
- Buy33.33%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Jul 26 at 03:14 AM
MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Rating of "Moderate Buy" by Analysts
- Tip Ranks · Jul 23 at 04:25 PM
MediciNova: Differentiated NAFLD/MASH Profile and Complementary APOC3 Positioning Support Unchanged $6 Target and Buy Rating
- PUBT · Jul 15 at 07:03 AM
MediciNova says SEANOBI-ALS expanded-access study of MN-166 reaches 200-patient enrollment target
- Unusual Whales · Jul 15 at 07:02 AM
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
- Tip Ranks · Jul 1 at 02:35 PM
Analyst Reiterates Buy on MediciNova as Advancing Pipeline and Upcoming ALS Catalysts Support Unchanged $6 Price Target
- PUBT · Jun 30 at 07:04 AM
MediciNova says US patent office allows ibudilast–anti-PD-1 combo claims for glioblastoma treatment
